Intestinal mucosal and luminal proteins

Intestinal mucosal and luminal proteins represent a broad, heterogeneous category of proteins located within the gastrointestinal lumen and the mucosal lining, serving as the primary site of action for several non-systemically absorbed therapeutic agents (DrugBank, 2024). This collective target includes various digestive enzymes, mucins, and membrane-bound transporters that facilitate nutrient processing, immune defense, and barrier maintenance (NCBI, 2023). Drugs such as sevelamer and colesevelam utilize this environment to bind and sequester dietary phosphate or bile acids, respectively, preventing their systemic absorption and thus managing conditions like hyperphosphatemia and hypercholesterolemia (PubMed, PMID: 11893944). Bismuth subsalicylate also interacts with these proteins to exert antimicrobial and antisecretory effects, often by binding to bacterial toxins or forming a protective layer over the gastric mucosa (PubChem, CID 16683005). Because this target encompasses a wide array of molecules rather than a single receptor or enzyme, its therapeutic utility is defined by the physical and chemical sequestration of ligands rather than specific signal transduction. Consequently, it is often classified as a non-specific or collective target in pharmacological databases.

Other names

Gut luminal proteinsIntestinal proteinsEnteric mucosal proteinsGastrointestinal proteins

Non-specific binding, adsorption, and sequestration of luminal ions (e.g., phosphate), bile acids, or bacterial toxins to prevent systemic absorption or provide mucosal protection (DrugBank, 2024; PubMed, PMID: 11893944).